Boehringer is a top 20 biopharmaceutical company by revenue and is the world’s largest private biopharma company, it is also a leader in liver disease R&D and has substantial experience in RNAi drug discovery and development.
The partnership is centred around Ochre’s liver regeneration research program, which seeks to identify medicines that promote the regeneration of cells lost in cirrhotic livers, helping restore normal metabolic function. Ochre is working on an updated 3 year strategy focused on late-stage chronic liver disease. This partnership fits into this strategy and enables significant investment in building our capabilities for late stage disease, including new genome-wide regeneration datasets and scalable human perturbation systems (cells, tissue, perfusion).
The deal brings in substantial capital to Ochre with $35m in upfront and near-term milestone payments, and up to $1bn of late preclinical, clinical, regulatory and commercial milestones, with tiered commercial royalties.
Read the interviews from the Financial Times and Endpoint News.
